Fürstenau M, Robrecht S, Schneider C, et al. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. Blood . 2025;145(12):1282 ...

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall ...

and obinutuzumab exceeded 80 months in patients with untreated or relapsed/refractory CLL. Almost 60% of patients with untreated disease had undetectable MRD (uMRD) status, as did 44% of the ...

CLL is a chronic disease that is typically difficult ... In addition, the researchers also examined the rate of undetectable measurable residual disease (MRD), a parameter that reflects how ...

Welcome to the Adaptive Biotechnologies first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

The results could herald a step change in treating CLL, which current treatments can ... as tested by flow cytometry and/or analysis for minimal residual disease (MRD), which measures residual ...

The Asia Pacific minimal residual disease (MRD) testing market is poised for remarkable growth, with projections indicating a robust 15.5% annual increase. Over the forecast period spanning from 2022 ...